Andersson AK, Ma J, Wang J, Chen X, Gedman AL, Dang J, et al. The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet. 2015;47:330–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Aoki Y, Watanabe T, Saito Y, Kuroki Y, Hijikata A, Takagi M, et al. Identification of CD34+ and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia. Blood. 2015;125:967–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burmeister T, Meyer C, Schwartz S, Hofmann J, Molkentin M, Kowarz E, et al. The MLL recombinome of adult CD10-negative B-cell precursor acute lymphoblastic leukemia: results from the GMALL study group. Blood. 2009;113:4011–5.

Article  CAS  PubMed  Google Scholar 

Gökbuget N, Stelljes M, Viardot A, Nachtkamp K, Steffen B, Schneller F, et al. First results of the risk-adapted, MRD-stratified GMALL trial 08/2013 in 705 adults with newly diagnosed acute lymphoblastic leukemia/lymphoma (ALL/LBL). Blood. 2021;138:362.

Article  Google Scholar 

Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland ML, Leguay T, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123:3739–49.

Article  CAS  PubMed  Google Scholar 

van Dongen JJ, van der Velden VH, Brüggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125:3996–4009.

Article  PubMed  PubMed Central  Google Scholar 

Gökbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120:1868–76.

Article  PubMed  Google Scholar 

Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113:4153–62.

Article  CAS  PubMed  Google Scholar 

van der Velden VH, Corral L, Valsecchi MG, Jansen MW, De Lorenzo P, Cazzaniga G, et al. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia. 2009;23:1073–9.

Article  PubMed  Google Scholar 

Burmeister T, Marschalek R, Schneider B, Meyer C, Gökbuget N, Schwartz S, et al. Monitoring minimal residual disease by quantification of genomic chromosomal breakpoint sequences in acute leukemias with MLL aberrations. Leukemia. 2006;20:451–7.

Article  CAS  PubMed  Google Scholar 

Brüggemann M, Raff T, Flohr T, Gökbuget N, Nakao M, Droese J, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116–23.

Article  PubMed  Google Scholar 

van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grümayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604–11.

Article  PubMed  Google Scholar 

Stutterheim J, van der Sluis IM, de Lorenzo P, Alten J, Ancliffe P, Attarbaschi A, et al. Clinical implications of minimal residual disease detection in infants with KMT2A-rearranged acute lymphoblastic leukemia treated on the interfant-06 protocol. J Clin Oncol. 2021;39:652–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gökbuget N. MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate? Hematology Am Soc Hematol Educ Program. 2021;2021:718–25.

Article  PubMed  PubMed Central  Google Scholar 

Kim R, Bergugnat H, Pastoret C, Pasquier F, Raffoux E, Larcher L, et al. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study. Blood. 2023;142:1806–17.

Article  CAS  PubMed  Google Scholar